Clinical trials: Anticoagulant Drugs
Antiphospholipid Syndrome
Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome
To Assess the Influence of Antiphospholipid Antibodies on INR Test Results in Patients with the Antiphospholipid Syndrome Anticoagulated with Vitamin-K Antagonists.
- Trial name
- NCT01660061
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Atrial Fibrillation New Onset
CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection
This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.
- Trial name
- NCT05127460
- Testing
- AI-enabled ECG-based Screening Tool
- Where
- Taiwan
- Volunteers
- 25,732 people
- Sponsor
- National Defense Medical Center, Taiwan
Atrial Fibrillation
Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial
Introduction: Patients with atrial fibrillation (AF) have a substantial risk of stroke and systemic embolism. Subclinical AF is often suspected to be the cause of stroke in these patients.
- Trial name
- SILENT (NCT02004509)
- Testing
- Anticoagulant
- Where
- Brazil
- Volunteers
- 2,054 people
- Sponsor
- InCor Heart Institute
Genital Haemorrhage
Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life
Little data are available on the genital haemorrhages in woman of childbearing age treated for venous thromboembolic disease by oral anticoagulant, especially the impact on the quality of life.
- Trial name
- GENB-OAB (NCT03772366)
- Where
- France
- Volunteers
- 453 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Venous Thrombosis
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
This is a randomized trial to compare intermittent compression devices with or without post-operative Arixtra (fondaparinux sodium) in women undergoing major abdominal surgery for known or presumed gynecologic malignancies.
- Trial name
- NCT00539942
- Testing
- Arixtra (fondaparinux sodium), Intermittent compression devices (ICD)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- EARLYmyo-LVT (NCT03764241)
- Testing
- Rivaroxaban, Vitamin K Antagonist
- Where
- China
- Volunteers
- 280 people
- Sponsor
- RenJi Hospital
Cardiovascular Diseases
Effectiveness of "Medisinstart"
"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition.
- Trial name
- NCT02261402
- Testing
- Medisinstart
- Where
- 67 sites in Norway
- Volunteers
- 1,480 people
- Sponsor
- Apokus AS
Atrial Fibrillation (AF)
AF-CARD Registry (Real-World Clinical Practice Registry of Patients With Atrial Fibrillation)
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and…
- Trial name
- AF-CARD (NCT07437456)
- Where
- Russia
- Volunteers
- 3,500 people
- Sponsor
- Eurasian Association of Therapists
Coagulation Disorder
Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts: Part 1: Single dose of…
- Trial name
- NCT06372483
- Testing
- VMX-C001, Rivaroxaban 20 mg Oral Tablet, Apixaban 5 mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Myeloma, Venous Thromboembolism
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
To evaluate: the incidence of venous thromboembolic event (VTE) the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an…
- Trial name
- MYELAXAT (NCT02066454)
- Testing
- Apixaban
- Where
- 19 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Grenoble
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Left Ventricular Thrombus
LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus
The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of…
- Trial name
- LVT Duration (NCT07246005)
- Testing
- Continue rivaroxaban or apixaban or warfarin, Discontinue rivaroxaban or apixaban or warfarin
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Queen Mary University of London
Stroke, Ischemic
Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial
The overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to…
- Trial name
- STROKE75+ (NCT07454707)
- Testing
- Edoxaban 15 mg, Aspirin or clopidogrel
- Where
- Canada
- Volunteers
- 1,204 people
- Sponsor
- Sunnybrook Health Sciences Centre
Total Knee Replacement, Total Hip Replacement
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs.
- Trial name
- NCT00074828
- Testing
- LY517717, enoxaparin
- Where
- 8 sites in Australia, Austria and 6 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Valvular Heart Disease
RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
RIvaroxaban for Valvular heart diseasE and atRial fibrillation trial (RIVER trial).
- Trial name
- NCT02303795
- Testing
- Rivaroxaban, Warfarin
- Where
- Brazil
- Volunteers
- 1,005 people
- Sponsor
- Hospital do Coracao
Atrial Fibrillation, Atrial Flutter
Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation
Study objective was to improve decision-making and thromboprophylaxis for patients with Atrial Fibrillation (AF) by developing and implementing a computerized decision support tool for individual patient-level decision-making…
- Trial name
- NCT02524977
- Testing
- Decision Support, Educational Intervention Only
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Deep Venous Thrombosis, Pulmonary Embolism
Drug Interaction Between Paracetamol and Warfarin
The objective of this study is to investigate whether paracetamol, given at therapeutic doses (2g/day and 3 g/day), may potentiate the anticoagulant effect of warfarin.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Stroke
- Trial name
- INPAWA2 (NCT01104337)
- Testing
- paracetamol
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hopital Lariboisière
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest
Nurse Training
The Effect of Pecha-Kucha Method Training on the Knowledge and Skills of Nurses Regarding Anticoagulant Drug Administration
The research was conducted between January 2025 and May 2025 using a randomized controlled experimental design with a pre-test-post-test pproach.
- Trial name
- NCT07736326
- Testing
- Pecha-Kucha
- Where
- Turkey (Türkiye)
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Istanbul Saglik Bilimleri University
Venous Thrombosis, Cardiovascular Diseases
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
To perform a randomized clinical trial comparing continuing one month of treatment with heparin in patients with deep venous thrombosis to standard care using heparin for five days and oral warfarin for three months.
- Conditions
- Venous Thrombosis, Cardiovascular Diseases, Venous Thromboembolism
- Trial name
- NCT00005684
- Testing
- warfarin, heparin
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)